Phenibut
Phenibut. Phenyl analog of GABA — crosses BBB. Primarily GABA-B agonist (baclofen-like) with weaker GABA-A activity. Voltage-gated Ca²⁺ channel inhibition at high…
Phenyl analog of GABA — crosses BBB. Primarily GABA-B agonist (baclofen-like) with weaker GABA-A activity. Voltage-gated Ca²⁺ channel inhibition at high doses. Produces anxiolysis + euphoria; serious dependence + withdrawal syndrome on chronic use (psychiatric-hospitalisation-level in case reports).
PK: STRIPPED. THE CITED PAPER REPORTS NO NUMBER OF ANY KIND — it is a Russian-language bioequivalence abstract whose entire finding is that two formulations of the same manufacturer "are bioequivalent in terms of pharmacokinetics", which is a statement about a RATIO and not a parameter. So both stored values are class 1. AND THE BIOAVAILABILITY HAS A TRACEABLE AND DISQUALIFYING ORIGIN: the only close figure in the indexed literature is "Absolute bioavailability was 64%", from a study whose own abstract says the distribution volume "only slightly surpassed the volume of extracellular body fluids IN RAT" — a rat study, of a citrate derivative rather than of phenibut itself. That is a species misattribution stacked on a compound misattribution, and it matches the stored value to within a percent. A systematic review of the clinical literature was checked for a replacement and reports case series and trials, not disposition parameters. The record is stripped rather than left asserting the solver defaults, which is the error this batch was opened by.
Sources: PMID:21809698